Latest Breaking News On - Poster area - Page 1 : comparemela.com

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMatthewa lobergSara ahmadiJoshua klopperRabail sadiqBoston convention exhibition centerVanderbilt university medical centerEndocrine societyVeracyte incJohns hopkins university school of medicineMolecular testingThyroid nodulesGenomic resourceIntelligent discoveryBoston conventionExhibition center

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaComunidad autonoma de catalunaUnited kingdomSarah mcleodDavid pattiAlison luckeyDennis riedlGabrielle kornmanDavid altaracHealth emergency preparednessGlobal antibiotic research development partnershipInnoviva incFoundation in genevaUs centers for diseaseInnoviva specialty therapeutics incInfectious disease global congress

Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases.

Comunidad autonoma de catalunaSouth africaUnited statesProduct serviceUniversity of pretoria on longhornEuropean congressPresent dataUniversal vaccine candidateOne healthClinical microbiologyInfectious diseasesPoster areaOpsonic iggLonghorn vaccines

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial of Viaskin™ Peanut in Toddlers Viaskin Peanut showed.

United statesFrance generalKatie matthewsMatthew greenhawtEleanor garrowAngela marcucciMatthewc greenhawtAnaphylaxis connection teamCompany adssAmerican college of allergyExchange commissionYear resultsOngoing phaseLabel extensionAmerican collegeNasdaq stock market

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 9, 2023DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPE.

United statesFrance generalMatthewc greenhawtAngela marcucciMatthew greenhawtKatie matthewsEleanor garrowAmerican college of allergyAnaphylaxis connection teamExchange commissionCompany adssYear resultsOngoing phaseLabel extensionAmerican collegeNasdaq stock market